Evidence map›Paper›PMID 37340319›Full record

ArticleAlzheimer's research & therapy2023

White matter hyperintensities and smaller cortical thickness are associated with neuropsychiatric symptoms in neurodegenerative and cerebrovascular diseases.

Miracle Ozzoude, Brenda Varriano, Derek Beaton, Joel Ramirez, Sabrina Adamo, Melissa F Holmes, Christopher J M Scott, Fuqiang Gao, Kelly M Sunderland, Paula McLaughlin and 42 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Neuropsychiatric symptom subtypes and dementia-associated neuropathologic change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Article
  7. Updates and future perspectives on neuropsychiatric symptoms in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors at 16 institutions in 3 countries.

Miracle OzzoudeTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Tower, 60 Leonard Avenue, 6th floor 6KD-407, Toronto, ON, M5T 2S8, Canada.
Brenda VarrianoTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Tower, 60 Leonard Avenue, 6th floor 6KD-407, Toronto, ON, M5T 2S8, Canada.
Derek BeatonData Science & Advanced Analytic, St. Michael's Hospital, Toronto, ON, Canada.
Joel RamirezL.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Sabrina AdamoGraduate Department of Psychological Clinical Science, University of Toronto Scarborough, Scarborough, ON, Canada.
Melissa F HolmesL.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Christopher J M ScottL.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Fuqiang GaoL.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Kelly M SunderlandRotman Research Institute of Baycrest Centre, Toronto, ON, Canada.
Paula McLaughlinNova Scotia Health, Halifax, NS, Canada.
Maged GoubranDr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Donna KwanCentre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.
Angela RobertsRoxelyn and Richard Pepper Department of Communication Sciences and Disorders, Northwestern University, Evanston, IL, USA.
Robert BarthaRobarts Research Institute, Western University, London, ON, Canada.
Sean SymonsSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Brian TanRotman Research Institute of Baycrest Centre, Toronto, ON, Canada.
Richard H SwartzSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Agessandro AbrahaoSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Gustavo SaposnikDivision of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Mario MasellisSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Anthony E LangDepartment of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
Connie MarrasDepartment of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
Lorne ZinmanSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Christen ShoesmithDepartment of Clinical Neurological Sciences, Western University, London, ON, Canada.
Michael BorrieRobarts Research Institute, Western University, London, ON, Canada.
Corinne E FischerDivision of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Andrew FrankDepartment of Medicine (Neurology), University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada.
Morris FreedmanRotman Research Institute of Baycrest Centre, Toronto, ON, Canada.
Manuel Montero-OdassoDepartment of Clinical Neurological Sciences, Western University, London, ON, Canada.
Sanjeev KumarDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Stephen PasternakSchulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Stephen C StrotherRotman Research Institute of Baycrest Centre, Toronto, ON, Canada.
Bruce G PollockDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Tarek K RajjiDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.
Dallas SeitzCumming School of Medicine, University of Calgary, Calgary, AB, Canada.
David F Tang-WaiDepartment of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
John TurnbullFaculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
Dar DowlatshahiDepartment of Medicine (Neurology), University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada.
Ayman HassanThunder Bay Regional Health Research Institute, Thunder Bay, ON, Canada.
Leanne CasaubonDepartment of Medicine, Division of Neurology, University of Toronto, Toronto, ON, Canada.
Jennifer MandziaDepartment of Clinical Neurological Sciences, Western University, London, ON, Canada.
Demetrios SahlasFaculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
David P BreenCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
David GrimesDepartment of Medicine (Neurology), University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada.
Mandar JogDepartment of Clinical Neurological Sciences, Western University, London, ON, Canada.
Thomas D L SteevesDivision of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Stephen R ArnottRotman Research Institute of Baycrest Centre, Toronto, ON, Canada.
Sandra E BlackL.C. Campbell Cognitive Neurology Unit, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Elizabeth FingerDepartment of Clinical Neurological Sciences, Western University, London, ON, Canada.
Jennifer RabinDr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
ONDRI Investigators
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Krembil Discovery Tower, 60 Leonard Avenue, 6th floor 6KD-407, Toronto, ON, M5T 2S8, Canada. carmela.tartaglia@uhn.ca.
Sunnybrook Health Science Centre · CAWestern University · CAUniversity Health Network · CASt. Michael's Hospital · CAUniversity of Toronto · CABaycrest Hospital · CACentre for Addiction and Mental Health · CAUniversity of Ottawa · CAMcMaster University · CACentral Michigan University · USMRC Centre for Regenerative Medicine · GBNorthwestern University · USNova Scotia Health Authority · CAQueen's University · CAThunder Bay Regional Research Institute · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuropsychiatric symptoms (NPS) are a core feature of most neurodegenerative and cerebrovascular diseases. White matter hyperintensities and brain atrophy have been implicated in NPS. We aimed to investigate the relative contribution of white matter hyperintensities and cortical thickness to NPS in participants across neurodegenerative and cerebrovascular diseases.

methodsFive hundred thirteen participants with one of these conditions, i.e. Alzheimer's Disease/Mild Cognitive Impairment, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson's Disease, or Cerebrovascular Disease, were included in the study. NPS were assessed using the Neuropsychiatric Inventory - Questionnaire and grouped into hyperactivity, psychotic, affective, and apathy subsyndromes. White matter hyperintensities were quantified using a semi-automatic segmentation technique and FreeSurfer cortical thickness was used to measure regional grey matter loss.

resultsAlthough NPS were frequent across the five disease groups, participants with frontotemporal dementia had the highest frequency of hyperactivity, apathy, and affective subsyndromes compared to other groups, whilst psychotic subsyndrome was high in both frontotemporal dementia and Parkinson's disease. Results from univariate and multivariate results showed that various predictors were associated with neuropsychiatric subsyndromes, especially cortical thickness in the inferior frontal, cingulate, and insula regions, sex(female), global cognition, and basal ganglia-thalamus white matter hyperintensities.

conclusionsIn participants with neurodegenerative and cerebrovascular diseases, our results suggest that smaller cortical thickness and white matter hyperintensity burden in several cortical-subcortical structures may contribute to the development of NPS. Further studies investigating the mechanisms that determine the progression of NPS in various neurodegenerative and cerebrovascular diseases are needed.

Indexed as

Cerebrovascular DisordersCognitive DysfunctionFrontotemporal DementiaParkinson DiseaseWhite MatterFemaleHumansMagnetic Resonance ImagingCerebrovascular diseaseCortical thicknessNeurodegenerative diseaseNeuropsychiatric symptomsWhite matter hyperintensities

Identifiers

PMID37340319
PMCPMC10280981
OpenAlexW4381433183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.